Notice for molnupiravir (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
molnupiravir
Date of review outcome
Lapse date
Type
Provisional approval
Indication
For treatment of COVID-19 in adults
Therapeutic area
Infectious diseases